This "Boring" Stock Has Soared 700% With No One Noticing

Hidden biopharma stock Over 24 years, Amgen has destroyed the S&P 500, turning a $1,000 investment into $7,600.

[{"selector":"#anim-18ba2f19-f731-4d45-bed4-7cfcc8de224b [data-leaf-element=\"true\"]","keyframes":{"transform":["translate(0%, 0%) scale(1.5)","translate(0%, 0%) scale(1)"]},"delay":0,"duration":2000,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}]

Strategic expansion and blockbuster medicine approvals have raised the company's market valuation to above $140 billion.

[{"selector":"#anim-1b9db943-d69d-428b-bc78-254b876e70d6 [data-leaf-element=\"true\"]","keyframes":{"transform":["translate(0%, 0%) scale(1.5)","translate(0%, 0%) scale(1)"]},"delay":0,"duration":2000,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}]

Nearly 40% of revenue comes from outside the U.S., fueling diversified global growth unmatched by competitors

[{"selector":"#anim-51a2d714-b4ee-4d62-b564-e3e81ceaf87d [data-leaf-element=\"true\"]","keyframes":{"transform":["translate(0%, 0%) scale(1.5)","translate(0%, 0%) scale(1)"]},"delay":0,"duration":2000,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}]

Amgen pays committed investors $247 annually on a $1,000 investment for 11 years with steadily expanding dividends.

[{"selector":"#anim-d9ee27f4-5a6c-4f6d-ac53-b8697732ba14 [data-leaf-element=\"true\"]","keyframes":{"transform":["translate(3.552713678800501e-15%, 0%) scale(1.5)","translate(0%, 0%) scale(1)"]},"delay":0,"duration":2000,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}]

Numerous late-stage cancer, inflammatory, and neurological medications aim to fuel organic growth beyond 2025.

[{"selector":"#anim-34b1be45-b0ca-479c-a06e-5425116c8f69 [data-leaf-element=\"true\"]","keyframes":{"transform":["translate(0%, 0%) scale(1.5)","translate(0%, 0%) scale(1)"]},"delay":0,"duration":2000,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}]

Acquisitions like the recent $28 billion purchase of Horizon Therapeutics offer additional immunotherapy revenue streams

[{"selector":"#anim-20c7f320-0ac0-4401-9d1d-194c98434d69 [data-leaf-element=\"true\"]","keyframes":{"transform":["translate(0%, 0%) scale(1.5)","translate(0%, 0%) scale(1)"]},"delay":0,"duration":2000,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}]

Leveraging manufacturing expertise to capture high-margin contract drug production deals from partners

[{"selector":"#anim-6a0cdd80-b396-4cda-94ac-f04a70249b5e [data-leaf-element=\"true\"]","keyframes":{"transform":["translate(23.13144248724051%, 0%) scale(1.5)","translate(0%, 0%) scale(1)"]},"delay":0,"duration":2000,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}]

Trading at reasonable forward P/E around 14 suggests room for more expansion as revenue diversifies globally

[{"selector":"#anim-c461911f-6f93-470e-8200-ec0f3fdb4b70 [data-leaf-element=\"true\"]","keyframes":{"transform":["translate(10.806417930201926%, 0%) scale(1.5)","translate(0%, 0%) scale(1)"]},"delay":0,"duration":2000,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}]

Long-term share price growth, medication innovation, and rising dividends might give patient investors outsized profits.

[{"selector":"#anim-429bb6f9-b8db-48d6-99d7-70b55ac656f1 [data-leaf-element=\"true\"]","keyframes":{"transform":["translate(12.501579023567905%, 0%) scale(1.5)","translate(0%, 0%) scale(1)"]},"delay":0,"duration":2000,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}]